Four things to know:
1. The company’s gross profit increased 8.5 percent to $213.8 million but net income decreased 31 percent to $11 million for the same period last year.
2. Product revenue increased 7.5 percent to $260.1 million compared to the third quarter of last year.
3. NuVasive’s total operating expenses rose $4.1 million to $183.2 million year-over-year.
4. NuVasive CEO J. Christopher Barry said the company’s “margin expansion demonstrates the ability to improve profitability” and it is “raising full-year 2019 financial guidance to reflect continued growth and confidence in the business.”
More articles on orthopedic devices:
Orthofix reports $40.5M loss & more: 7 device company notes
SeaSpine posts $39.9M Q3 revenue
Stryker Q3 net sales hit $3.6B; spine sales up 35%
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
